DePuy Synthes Products acquired 3D printing technology from Tissue Regeneration Systems (TRS) to offer patient-specific, bioresorbable implants to treat orthopaedic and craniomaxillofacial deformities and injuries. Financial terms were not disclosed.
The technology will support DePuy's trauma portfolio, which remains a priority platform for the company's growth. (ORTHOWORLD estimates that DePuy's 1Q17 trauma segment growth was flat year over year, after closing 2016 at +1.5% vs. 2015.)
The two companies commenced collaboration on 3D printing in 2014, developing resorbable implants to treat large bone segment defects. Investments in 3D tools continued in 1H16, when Johnson & Johnson announced a partnership with HP on use of the technology to develop patient-customized products that can be manufactured quickly, and also noted refinements to a 3D-printed tri-flange acetabular hip system for severe revision cases.
The use of 3D printing and additive manufacturing is expected to expand in the trauma space as companies seek technologies that promote bone fusion and support the creation of custom implants.
Sources: DePuy Synthes; ORTHOWORLD Inc.